Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Philogen SpA ( (IT:PHIL) ) has shared an update.
Philogen S.p.A. has announced an update on its share buyback program, purchasing 8,333 shares between June 23 and June 27, 2025, at an average price of Euro 22.9635 per share. This move reflects the company’s ongoing strategy to manage its share capital and potentially enhance shareholder value, as it now holds 355,225 ordinary shares, representing 0.8747% of its share capital.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR33.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen S.p.A. is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products for treating high-mortality diseases. The company focuses on discovering and developing targeted anti-cancer drugs using high-affinity ligands for tumor markers, primarily through tumor targeting and vascular targeting strategies.
YTD Price Performance: 13.33%
Average Trading Volume: 21,207
Technical Sentiment Signal: Buy
Current Market Cap: €646.3M
See more insights into PHIL stock on TipRanks’ Stock Analysis page.